Artificial intelligence in drug discovery and personalized medicine: Transforming the future of pharmaceutical research

The integration of artificial intelligence (AI) into drug discovery and personalized medicine has revolutionized the pharmaceutical industry by accelerating drug development and optimizing patient-specific treatments. Traditional drug discovery methods are often time-consuming, costly, and inefficient, with high attrition rates. AI-driven approaches leverage machine learning (ML), deep learning (DL), and big data analytics to streamline target identification, optimize lead compounds, and predict clinical outcomes with unprecedented accuracy. AI-based drug design, predictive analytics for pharmacokinetics, and toxicity assessment have significantly improved the efficiency of drug development pipelines. Furthermore, AI enables personalized medicine by analyzing multi-omics data, electronic health records, and real-world evidence to tailor treatments based on genetic, environmental, and lifestyle factors. Companies such as Atomwise, Insilico Medicine, and Tempus have demonstrated AI’s potential in identifying novel drug targets and designing personalized treatment regimens. However, challenges such as data privacy, algorithmic bias, and regulatory compliance remain key obstacles to widespread adoption. This review provides a comprehensive overview of AI’s role in transforming drug discovery and personalized medicine, addressing both its advantages and limitations while exploring future directions, including the integration of quantum computing and explainable AI. AI-driven innovations are poised to redefine pharmaceutical research, offering faster, safer, and more effective therapies for complex diseases.